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ABSTRACT
Introduction: Obese women are more likely to
develop a surgical site infection (SSI) following
caesarean section (CS) than non-obese women.
Negative pressure wound therapy (NPWT) is
increasingly being used to reduce SSI with limited
evidence for its effectiveness.
Objectives: To determine the clinical and cost-
effectiveness of using NPWT in obese women having
elective and semiurgent CS.
Methods and analysis: A multisite, superiority
parallel pragmatic randomised controlled trial with an
economic evaluation. Women with a body mass index
(BMI) of ≥30, booked for elective and semiurgent CS
at 4 Australian acute care hospitals will be targeted.
A total of 2090 women will be enrolled. A centralised
randomisation service will be used with participants
block randomised to either NPWT or standard surgical
dressings in a 1:1 ratio, stratified by hospital. The
primary outcome is SSI; secondary outcomes include
type of SSI, length of stay, readmission, wound
complications and health-related quality of life.
Economic outcomes include direct healthcare costs
and cost-effectiveness, which will be evaluated using
incremental cost per quality-adjusted life year gained.
Data will be collected at baseline, and participants
followed up on the second postoperative day and
weekly from the day of surgery for 4 weeks. Outcome
assessors will be masked to allocation. The primary
statistical analysis will be based on intention-to-treat.
Ethics and dissemination: Ethics approval has been
obtained from the ethics committees of the
participating hospitals and universities. The findings of
the trial will be disseminated through peer-reviewed
journals, national and international conference
presentations.
Trial registration number: ACTRN12615000286549;
Pre-results.
BACKGROUND AND RATIONALE
Between 187 and 281 million surgical proce-
dures are performed around the world each
year, or 1 for every 25 people.1 Surgical site
infections (SSIs) are deﬁned as infections
occurring up to 30 days after surgery that
affect the incision, deep tissue at the oper-
ation site or involve the organs or body
spaces.2 Of concern is that SSIs occur in up
to 30% of all surgical procedures, and are
the third most commonly reported hospital
acquired infection in many countries.3–5 SSIs
have many negative effects including increas-
ing the risk of death, prolonging hospitalisa-
tion and increasing costs.4
Obesity is an independent predictor of
SSI.6 7 Obese pregnant women are twice as
likely to have a caesarean section (CS) than
non-obese women.8 9 Postoperative infection
is a potential complication of all surgeries
including CS; however, overweight and obese
women are three times more likely to
develop a SSI.10 SSI extends hospital length
of stay (HLOS) by up to 6 days in women
undergoing obstetric and gynaecological
surgery and hospital readmission is more
likely, increasing hospital costs by US$14 000
for each SSI.11
The use of negative pressure wound therapy
in primary wounds
Negative pressure wound therapy (NPWT) is
widely used, particularly in the management
of wounds healing by secondary intention
and for skin grafts.12–15 However, NPWT is
increasingly being applied prophylactically to
closed surgical wounds in high-risk popula-
tions to reduce the incidence of SSI. This
use of prophylactic NPWT is generally
applied to wounds perceived as being at high
risk of SSI, for example, CS incisions in
obese women.14 15 A recent Cochrane review
concluded that evidence for the clinical
effectiveness of prophylactic NPWT in redu-
cing SSI and wound dehiscence is
inconclusive.16
Two further randomised controlled trials
(RCTs) of NPWT have subsequently been
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published; both were feasibility studies.17 18 One of these
trials examined the use of NPWT in 70 patients under-
going primary hip replacement.18 The other pilot
study17 recruited 92 women undergoing elective CS and
has demonstrated that a deﬁnitive trial is feasible.
Neither of these trials was powered to ﬁnd an effect, so
the beneﬁts or harms of NPWT for prophylactic use
remain unclear.
Thus, a RCT to evaluate the clinical and cost-
effectiveness of NPWT in obese women undergoing CS
is timely and responds to the imperative to provide
much-needed evidence to guide practice in a rapidly
developing and costly area of healthcare.
Primary objective
To compare the effects of prophylactic NPWT and stand-
ard surgical dressings on the incidence of SSI in obese
women undergoing CS.
Secondary objectives
To compare: (1) the incidence of superﬁcial, deep,
organ/space SSI; (2) the number of dressing changes;
(3) the number and type of wound complications (ie,
dehiscence, haematoma, seroma, adverse events (AEs));
(4) the number of hospital readmissions; (5) HLOS
(days); (6) health-related quality of life (QoL); and (7)
direct healthcare costs in obese women undergoing CS
who receive prophylactic NPWT with women who
receive standard surgical dressings.
Study design
Multicentre, parallel group, pragmatic, randomised con-
trolled superiority trial.
METHODS
Study setting and population
Four acute care public hospitals offering obstetric ser-
vices in Queensland, Australia, have agreed to partici-
pate. Across the four sites, the number of births ranges
from 2400 to 10 000 per annum. The study population
will consist of 2090 women with a BMI of ≥30, undergo-
ing either elective or semiurgent CS.
Eligibility criteria
According to national and international guidelines, CS
urgency is based on these four categories: (1) life-
threatening to woman or fetus; (2) maternal or fetal
compromise, not life-threatening; (3) needing earlier
CS than planned without maternal or fetal compromise;
and (4) a scheduled time acceptable to the woman and
CS team.19 20
Inclusion criteria:
1. Women booked for elective CS surgery (category 4);
2. Women whose condition changes to require a semiur-
gent CS (categories 2–3);
3. Recorded pre-pregnancy BMI of ≥30 at the ﬁrst ante-
natal visit; and
4. Able to provide written informed consent.
Exclusion criteria:
1. Women who require an urgent CS (category 1) at
any point;
2. Existing infection after admission to hospital in
labour/immediately prior to CS;
3. Previous participation in this trial; and
4. Unable to speak or understand English, with no
interpreter available.
Interventions
While this will be a pragmatic trial, a checklist based on
published current clinical practice guidelines and
Queensland Maternity and Neonatal Guidelines will be
used to standardise the CS surgical procedure. The par-
ticipating obstetrician’s clinical judgement may produce
slight variation in practice in the type of wound closure
(ie, closure of facial layer as well as rectus muscle); selec-
tion of suture materials (ie, staples vs subcuticular
absorbable suture for skin); and standard dressing pref-
erence (eg, semipermeable vs hydrocolloid). There is
no evidence to suggest that the aforementioned minor
variations in clinical practice increase the risk of SSI.
Intervention
At the completion of skin closure, women randomly allo-
cated to the NPWT arm of the trial will receive a PICO
(Smith & Nephew, Hull, UK) dressing applied by the
obstetrician under sterile conditions. The PICO product
was chosen because it is lightweight and disposable, sig-
niﬁcantly cheaper than other options, and has per-
formed well in a pilot study.17 It comprises a small,
discrete pump, powered by two AA-lithium batteries with
a highly absorbent dressing that holds the wound
exudate away from the skin, thus negating the need for
a bulky canister. The polyurethane foam dressing will be
secured over the incision by the application of an adhe-
sive drape. A tube is embedded into the foam, and con-
tinuous negative pressure of 80 mm Hg will be applied
to the dressing.
Control
Women in the control arm will have a standard dressing
based on the obstetrician’s usual preference, applied
according to the manufacturer’s recommendations after
skin closure. In both groups, we anticipate the dressing
will remain in situ for 4– 5 days, unless it becomes soiled
or dislodged, in which case a new dressing of the same
type will be applied. Given the pragmatic nature of this
trial, the number of days dressings are left in situ and
the number of dressings used will be recorded. To
ensure consistency, clinicians providing care to the
target population at each of the sites will receive trial-
speciﬁc education (NPWT and standard). The research
assistants (RAs) who will also receive trial-speciﬁc train-
ing will be available to clinical staff during business
hours to provide ongoing training and support about
correct use of the dressings, as well as monitoring
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dressing changes and completing documentation daily
to assess protocol compliance and outcomes. If our
monitoring shows variation from the proposed protocol,
this variation will be used as a factor in the analyses.
Outcome measures
The primary outcome is the incidence of an SSI in the CS
wound at any time up to 28 days after surgery.
The following secondary outcomes will be assessed: depth
of SSI, that is, superﬁcial, deep or organ/body space3;
number of dressing changes; presence and number of
wound complications (ie, dehiscence, haematoma,
seroma, blisters).
Other secondary outcomes: HLOS will be measured in
days; number of hospital readmissions will be measured
within 4 weeks from the day of surgery. The secondary
outcome, health-related QoL will be assessed using the
Short Form (SF)-12v2 (acute 1-week recall). The SF-12v2
will be administered at baseline (ie, recruitment at >36/
40 weeks in women having elective CS, or on the day of
CS for women undergoing semiurgent CS), and via tele-
phone interview weekly for four consecutive weeks after
surgery. Direct healthcare costs will be included as part
of an economic evaluation.
Participant timeline and trial duration
Participants will be enrolled in the study for 28 days
from the day of surgery (Table 1). The project will take
up to 5 years to complete, with recruitment and data col-
lection expected to occur over 3.5 years. Participants will
exit the trial when they: withdraw consent; have been in
the trial for 28 days postrandomisation; are lost to
follow-up; die; or for another reason have to exit based
on the clinical judgement of the attending healthcare
professional.
Sample size
The sample size was calculated based on the primary
outcome, SSI. Based on other related published
studies,21 22 we conservatively estimate the baseline SSI
incidence in obese CS women to be 15%. Following dis-
cussions with infectious disease experts and obstetri-
cians, we have accepted an absolute difference between
groups of 5% to be clinically important. Therefore, to
achieve over 90% power to test the superiority of SSI
incidence between groups, 950 women per group will be
required (Power Analysis & Sample Size system (PASS,
V.12), NCSS). To allow for attrition, a further 10%
(n=95) will be recruited to each group for a total sample
of 2090 (1045/group). We anticipate recruiting approxi-
mately 600 women per year, thus recruitment should be
completed in about 3.5 years.
Recruitment of participants
We will use a staged approach to recruitment, starting at
one site to test procedures, prior to starting at the other
sites. All obese women will be given an information bro-
chure informing them of the trial during their routine
antenatal visit at 36 weeks. This strategy will facilitate
further discussion and assist with consent processes in
labour in the event that a semiurgent CS is required.
Women booked for an elective CS will be given the
opportunity to provide written consent during their
antenatal visit (36/40 weeks). On the day of surgery,
women undergoing elective CS will be screened to
ensure they continue to meet the inclusion criteria;
those who have not yet provided written consent will be
invited to do so. Women undergoing semiurgent CS will
be consented on the day of surgery. Figure 1 shows
anticipated participant ﬂow through the study.
Implementation of sequence generation and allocation
concealment
Women booked for elective CS will not be randomised
at recruitment as the long time lag between randomisa-
tion and receiving the intervention which could lead to
poor adherence to allocation and loss to follow-up. All
women who continue to meet the eligibility require-
ments will be randomised using a centralised, independ-
ent, web-based randomisation system. The RA will
randomise participants in the operating room at the
start of their CS procedure and advise the operating
obstetrician and nursing staff of the allocated treatment
as close to the end of the procedure as possible in order
to minimise performance bias. The allocation sequence
will be used to ensure allocation concealment. To
reduce predictability of a random sequence, randomly
varying block sizes of four, six and eight will be used.
Blinding
This pragmatic trial tests a clinical intervention that is
not amenable to protection against performance bias
through the blinding of participants, clinical staff or
data collectors.
To minimise the potential for outcome detection bias,
an expert clinician, blinded to group allocation, will
assess the data to determine the primary outcome. The
trial statistician and coordinating principal investigator
(PI) will also be blinded. It is unlikely that entries to the
medical records and hospital databases will be falsiﬁed;
thus, lack of blinding for these outcomes should not
affect the data integrity. Subjective outcomes (wound
complications, QoL) are reported by patients or
observed by RAs, who cannot be blinded because they
need to check the dressings and document participants’
responses.
Performance bias is a consideration when clinical staff
cannot be blinded. To assess the risk of performance
bias, a standardised set of questions will be used to docu-
ment the number of dressing changes and/or protocol
violations occurring during the hospital stay, and follow-
ing discharge. We considered using dressings where
tubing was attached to a suction apparatus in both
groups; however, participants, staff and data collectors
would almost certainly be aware if suction was activated
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Table 1 Timeline of trial activities
Study period
Allocation (day 0)
Enrolment
Elective
CS
Semiurgent
CS Postallocation
Time point
2 days
postoperative
7 days
postoperative
14 days
postoperative
21 days
postoperative
28 days
postoperative Closeout
Enrolment Inpatient Day of surgery up to 28 days
Eligibility screen
36/40-week antenatal visit X X
Day of CS X X
Informed consent
36/40-week antenatal visit X X
Day of CS X X
Baseline data
36/40-week antenatal visit X X
Day of CS X X
Randomisation during CS
procedure
X X
InterventionS (4–5 days insitu)
NPWT dressing X X X X X
Standard dressing X X X X X
Assessments
Baseline
Pre-pregnancy BMI/height/weight X
Parity/gravidity X
Comorbidities X
SF-12 v2 X
Preoperative data X
Surgical data form X
Outcome variables
Dressing change/reason X
Allocated dressing X
Temp/HR/RR X
Wound complications X
Patient satisfaction X
Prophylactic ABs/type X
AB route X
AB s 24 h postoperative X
Inpatient SSI screening X
Blood culture X
AB therapy X
Continued
4
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and we decided it was most important to measure ‘real-
world’ effects and conduct a pragmatic trial.
Data collection
The RAs will collect SSI-related data on day 2 (postsur-
gery) using a structured form. In Queensland, Australia,
the Centre for Healthcare Related Infection Surveillance and
Prevention provides guidelines identifying SSI signs and
symptoms (ie, redness, swelling, pain/tenderness, dehis-
cence, watery or purulent discharge), both during hospi-
talisation and after hospital discharge. Data which will
be collected from a variety of sources including chart
audit, direct observation and patient self-report both
during hospitalisation and after discharge. RAs will
record dressings used and antibiotic medication. Data
collection will occur on weekdays (Monday to Friday).
Clinical outcome data will be collected by the RAs retro-
spectively though telephone interviews and by accessing
participants’ medical records.
After hospital discharge, all women will be telephoned
weekly (from their day of surgery) and outcomes
assessed using a series of questions, which have been
used successfully in other research in this area.17 18 22
Seven-day recall of SSI symptoms and related resource
use including health professional visits (eg, consultations
with general practitioners (GPs)) was demonstrated as
being feasible in a recently published pilot trial17 and
will allow accurate SF-12v2 and costing data to be
collected.
RAs will collect and directly enter data while in the
clinical areas, using portable computers with a purpose-
built database and form-based interface (ie, Research
Electronic Data Capture (REDCap) database). Clinical
characteristics such as age, comorbidities and other risk
factors for SSI, such as nicotine use and length of oper-
ation, will be collected at baseline. Recruitment and
data collection will be monitored by the clinical trial
coordinator (CTC) weekly and monthly reports will be
presented to the study investigators. While there is a
potential for loss to follow-up, our pilot study has
demonstrated retention rates of >85%.17 We will also use
standard procedures, such as recording alternative
phone and email contacts for participants and GPs, in
order to assist with tracing women who may have moved
house/changed internet providers, etc.
Ascertainment of the primary outcome
SSI-related data will be given to the two blinded expert
clinicians, who will compare the data against criteria
deﬁned by the Centres for Disease Control and Prevention
Guideline for Prevention of SSI3 to decide if a SSI exists. We
will use decision rules to ascertain the primary outcome.
If the two blinded expert clinicians disagree on whether
the patient has sustained a SSI within the 28-day post-
operative period, we will use the following combinations
with regard to wound infection: yes/no, yes/unsure, no/
unsure:
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1. If the two assessors say: ‘yes/unsure’ then we will say
the patient has a SSI, using the data provided by the
assessor who said ‘yes’.
2. If the two assessors say: ‘no/unsure’ then we will say
the patient does not have a SSI.
3. If the two assessors say: ‘unsure/unsure’ then we will
say the patient does not have a SSI.
4. If the two assessors say: ‘yes/no’ then the third asses-
sor will be consulted and will decide if there is a SSI
or not. The third assessor’s decision will be ﬁnal. If
s/he is unsure whether the patient has a SSI or not,
then the patient will be considered not to have a SSI.
Training, outcome assessment and treatment fidelity
Adhering to Good Clinical Practice (GCP) recommenda-
tions,23 this multisite study will have an experienced CTC
coordinating the RA training, and site and data monitor-
ing. Trial-speciﬁc RA training to assess the patient’s inci-
sion/dressing site will be provided by a tissue viability
nurse. Additional training in the use of the PICO NPWT
dressing product will be provided by a Smith & Nephew
clinical nurse educator with specialist knowledge but
with no role in the design, analysis or reporting of the
study. Involving a product specialist in the training of the
RAs and clinicians who will be using the PICO product
ensures that all end-users receive comprehensive and
consistent information relative to the appropriate use
and management of the study intervention. The RAs will
undergo group and individual onsite training to ensure
consistency across the four sites. Areas covered will
include recruitment and data collection processes, use of
the central randomisation service and database.
Consistent with GCP recommendations,23 a standar-
dised operating procedure manual has been developed
to provide more speciﬁc detail on the protocol, plans
for dealing with intervention ﬁdelity issues, and monitor-
ing the delivery and receipt of the intervention.
Assessment of treatment ﬁdelity will focus on type of
dressing used, duration of use and number of dressing
changes. While this is a pragmatic trial, obtaining infor-
mation on intervention ﬁdelity may help to explain
study results. All members of the research team, includ-
ing RAs, will be provided with training, a procedure
manual and a DVD detailing the NPWT dressing appli-
cation to ensure protocol consistency. A trial-speciﬁc
training programme and ongoing education sessions tar-
geting obstetricians, operating room staff, midwives and
nurses will also be implemented at each site.
Withdrawal
If a participant decides to withdraw from the trial after
consent is given, any existing data obtained during the
trial will be retained and no further follow-up data col-
lected. A withdrawal form will be completed and reasons
for withdrawal noted. Patients who withdraw from rando-
mised treatment prior to randomisation will be left in
the study and reported in the ﬂow chart as ‘not receiv-
ing randomised intervention’. Patients who withdraw
after they have received the intervention (ie, after dress-
ing application) will also be included and reported in
the ﬂow chart as ‘receiving randomised treatment’.
Data management
All data will be managed using a centralised REDCap
(Nashville, Tennessee, USA) database repository, hosted
on a dedicated secure server within the Clinical Trials
Unit at Grifﬁth University. The trial statistician will not
have access to the database to ensure he remains
Figure 1 Anticipated participant
flow through study.
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blinded to group allocation. This database enables dif-
ferent levels of data access, allowing researcher control
over who sees the ﬁles and what they can do with them.
Data access will therefore be restricted and all data pass-
word protected. Each site RA will have a level of access
to the database speciﬁc to their site and position, and
will use a password-protected tablet computer for data
entry into REDCap.
An electronic case report form (eCRF) will be devel-
oped in collaboration with the trial statistician, coordin-
ating PI and CTC. The eCRF will be hosted on the
REDCap database within the Grifﬁth University’s
Clinical Trials Unit. Source data will be entered by the
site RAs, who will receive trial-speciﬁc training in the use
of the eCRF. All entered data will be directly exported
into the IBM Statistical Package for the Social Sciences
(SPSS V.22.0, New York, USA) for analysis.
Identifiable data
For the purposes of statistical analysis, data will be anon-
ymised and collated by the CTC and uploaded into
SPSS. Identiﬁable data will be entered on the eCRF to
enable follow-up. These data will be de-identiﬁed when
transferred to the statistical database. Participants will be
identiﬁed on the statistical database using a unique code
and hospital site initials.
Statistical analysis
Primary analyses
Prior to analysis, a rigorous process of data cleaning to
check outlying ﬁgures, missing and implausible data
against source data will be undertaken. Baseline
characteristics of the patients in each arm of the trial
will be calculated using descriptive statistics. We will
employ an intention-to-treat approach for the primary
analysis with the population deﬁned as all trial partici-
pants who completed the baseline assessment and
underwent surgery and received the intervention. AEs
will be analysed and reported on a per protocol analysis.
The incidence of SSI per 1000 patients between groups
will be compared. Risk ratios (RR), 95% CIs and
p values assuming a 5% signiﬁcance level will be
presented. For the primary outcome, the number
needed to treat and absolute risk reduction will be calcu-
lated from the RR. While we do not anticipate differ-
ences between groups in terms of known or unknown
prognostic factors due to randomisation, adjusted ana-
lyses using multivariate logistic regression models will be
used if any difference in prognostic variables is detected.
Despite every effort to minimise missing values it is pos-
sible that some may occur. We will evaluate the utility of
empirical imputation methods in such cases and only
impute them if the explanatory power of the empirical
imputation models is robust. To assess the representative-
ness of the sample, we will compare the characteristics
of the women in our sample with secondary data avail-
able at state and national levels.
Secondary analyses
Secondary end points will be compared between groups
using statistical methods appropriate to the distribution
of measures. A random sample of 5% of the data will be
rechecked for accuracy against source data. RRs with
95% CI will be calculated for clinical outcome data.
Analysis will be performed by one of the study investiga-
tors (blinded to group allocation), trained in
biostatistics.
Economic evaluation
Direct costs to the healthcare system will be obtained
from patient records/hospital cost centres (during hos-
pital admission) and self-reported by women (weekly for
4 weeks post surgery). Resources costed during admis-
sion will include dressings and related wound manage-
ment products, medications related to SSI (ie, use of
antibiotics), and resources used to manage any adverse
effects of the dressing. Use of dressings, medications
and health professional appointments related to wound
management will be recorded at weekly intervals for
4 weeks following surgery. Direct costs will be assigned
using standard costing sources (eg, Medicare Beneﬁts
and Pharmaceutical Beneﬁts Schedules; Independent
Hospital Pricing Authority). The Australian-reﬁned
diagnostic-related groups will be used to indicate the
costs associated with each hospital admission, adjusted
for HLOS.
Cost-effectiveness analysis
A within-trial economic evaluation will be undertaken
from the health system perspective to compare the costs
and effects of NPWT, relative to the standard dressing.
Parametric (eg, analysis of covariance) or non-
parametric bootstrapping techniques24 will be employed
to compare the mean difference in the total costs
between groups. The cost-effectiveness analysis will be
undertaken based on the primary outcome measure
(SSI). Additionally, a cost-utility analysis will be per-
formed using the quality-adjusted life year (QALY) as
the outcome measure. The QALY gain associated with
NPWT will be estimated based on SF-12v2 utility
weights.24 Uncertainty around the incremental cost-
effectiveness ratios will be tested using one-way sensitivity
analysis and non-parametric bootstrapping methods.24
The cost-effectiveness estimates will inform recommen-
dations on adopting NPWT dressings for CS surgical
wounds in clinical practice.
Safety and data monitoring
An AE is deﬁned as an untoward medical occurrence
experienced by the participant, whether or not consid-
ered treatment related.25 In this trial, AE will be classi-
ﬁed as non-serious (infection, pain, maceration, odour)
and serious (dehiscence, return to theatre). Both types
of AE would be expected to occur equally in both treat-
ment groups. Patients will be monitored for potential
AEs, serious and non-serious. All AEs reported will be
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assessed to determine whether further diagnostic investi-
gation or treatment is warranted. If an AE occurs, appro-
priate treatment will be given. Monitoring and reporting
of suspected unexpected adverse reactions (SUSARs)
will be performed by the site PI and the research team.
All SUSARs will be recorded on a dedicated eCRF.
Serious AEs associated with the intervention are consid-
ered unlikely, although if any are reported the relevant
Human Research Ethics Committees will be notiﬁed,
with appropriate notiﬁcation of the Therapeutic Goods
Administration (TGA) as required.
The results of the trial will be reviewed every 6 months
by an independent Data Safety and Monitoring
Committee (DSMC) including an obstetrician, a statisti-
cian and a tissue viability nurse, all of whom will be inde-
pendent of the study. The DSMC has the ability to
terminate the trial prematurely if there is unacceptable
harm associated with the treatment.26 If requested by
the DSMC, an interim analysis will be performed by a
statistician (independent of the DSMC), blinded for the
treatment allocation.
Auditing
Data monitoring of this trial will ensure compliance with
GCP.23 The participating sites will provide access to all
trial-related source data/documents and reports for the
purposes of monitoring, auditing and inspection by
local authorities. The CTC will undertake monitoring in
relation to the accuracy of the case report data collected
by the site RAs. During the trial, the CTC will use source
data to verify the data entered by the RAs into the eCRF.
Ethics and dissemination
This trial has been approved by the relevant hospital
ethics boards and the respective universities where the
PIs are employed. This study will be conducted in
accordance with the principles of the Declaration of
Helsinki (1996), and the Australian National Health and
Medical Research Council (NHMRC) National
Statement.27
Dissemination strategies will include knowledge trans-
lation events involving opinion leaders and stakeholders.
Findings will be presented at local hospital and other
fora and a press release will be prepared. A succinct
non-technical paper discussing the relevance of ﬁndings
and application to practice, and recommendations for
future research, will be prepared and disseminated to
the colleges representing the relevant health profes-
sional groups. Abstracts will be submitted to major inter-
national meetings of infection control, nursing/
midwifery and medical groups. We envisage the results
will be published in high-impact generalist and specialist
journals. We will bring the published study to the atten-
tion of the Cochrane Wounds Group and the authors of
the relevant Cochrane review to ensure early inclusion
in review updates. The results will have international
application and we anticipate that they will be rapidly
adopted and cited within the GCP literature.
DISCUSSION
Despite a lack of rigorous evidence to support either
clinical or cost-effectiveness, NPWT is increasingly being
used as a prophylaxis against SSI in high-risk surgical
groups such as obese women undergoing CS. To the best
of our knowledge, this RCT will be the largest of its kind
in this area. It has signiﬁcant potential to inform practice
because it assesses the clinical and cost-effectiveness of
using NPWT in a patient population at high risk of incur-
ring an SSI. A RCT design with a sufﬁciently large
sample is time consuming and expensive to undertake,
but it is nevertheless necessary to determine the efﬁcacy
of NPWT in the management of surgical incisions.
Our trial has several strengths. First, the RCT design
with a robust randomisation process will ensure that any
difference in outcomes between the groups is attribut-
able to the intervention. Second, a pragmatic approach
allows testing of an intervention that reﬂects the reality
of the clinical environment relative to study population,
intervention, comparator and outcomes.26 Third, an
independent clinician, blinded to group allocation will
assess these data to determine SSI status. Fourth, the
embedding of an economic evaluation responds to the
need to provide healthcare administrators and decision-
makers with meaningful cost-effectiveness data. Finally,
this trial is independent of industry funding, and there-
fore minimises potential for a conﬂict of interest which
may bias the results.
While we envisage that the results of this trial will
provide clinicians with deﬁnitive answers around the
effectiveness of NPWT in this speciﬁc patient popula-
tion, undertaking this 5-year trial is not without its chal-
lenges, including meeting our recruitment targets
within a 3.5-year timeframe. For each hospital site, yearly
recruitment targets will need to range from 120 to 200
women. To maximise both recruitment and generalis-
ability, we will include women who are undergoing both
elective and semiurgent CS. Another major challenge is
the potential for missing outcome data due to partici-
pant attrition as participants in this study will typically be
busy with childcare and other commitments postopera-
tively. Yet in a recent pilot study, participant attrition was
less than 10%,17 which is considered acceptable.
Maximising participant retention over a 4-week follow-up
period will be achieved by the RAs meeting women
face-to-face during pregnancy/labour and again post-
operatively. These meetings will enable a relationship of
trust to be developed and allow the RAs to resolve any
queries promptly. It will also provide opportunities for
the RAs to reconﬁrm women’s contact details and
remind them about the four weekly telephone follow-
ups. In the event that an RA is unsuccessful in their ﬁrst
attempt to contact women following discharge, they will
try again, perhaps using their alternative contact details.
Finally, during the 3.5-year data collection period, there
may be clinical innovations introduced that potentially
inﬂuence the trial outcomes (ie, ‘history’). However, we
anticipate that both groups to be equally inﬂuenced.
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